CAJ | 학술논문

目的分析瑞舒伐他汀钙对高脂血症合并高血压患者的疗效. 方法选取我院2011年3月至2012年10月收治的首次诊断为高脂血症合并高血压的患者112例,按照随机分组的方法分为治疗组与对照组,各56例,对照组采用常规的降压药物氨氯地平5mg/d进行口服治疗,治疗组患者在对照组治疗的基础上行瑞舒伐他汀10mg/d口服.治疗1个月之后比较2组患者的血压、血脂、超敏C-反应蛋白和不良反应发生情况. 结果治疗1个月后,两组患者的收缩压和舒张压均较治疗前降低(对照组t=4.95、2.87,治疗组t=5.03、2.94,均P＜0.01),治疗组低密度脂蛋白胆固醇、三酰甘油、总胆固醇分别为(1.75±0.68) mmol/L、(1.71±0.18) mmol/L、(3.18±0.47)mmol/L,对照组分别为(2.64±0.72) mmol/L、(1.89±0.25) mmol/L、(4.23±0.56) mmol/L),两组治疗后均降低(t值分别为2.77、3.16、2.59,均P＜0.05),与对照组相比治疗组的下降幅度更为明显(t值3.96、3.42,均P＜0.001)；高密度脂蛋白胆固醇(1.09±0.23) mmol/L较治疗前(0.72±0.24)mmol/L增加(t=3.01,P=0.004),治疗组超敏C-反应蛋白由(4.97±0.13) mg/L下降(1.32±0.17)mg/L(t=4.40,P＜0.001).两组患者肝肾功能无显著的变化,未出现严重的不良反应. 结论瑞舒伐他汀钙治疗可以有效地降低血中低密度脂蛋白胆固醇、三酰甘油和超敏C-反应蛋白,提高高密度脂蛋白胆固醇,该方案可以更有效地控制血压.
목적 분석서서벌타정개대고지혈증합병고혈압환자적료효. 방법 선취아원2011년3월지2012년10월수치적수차진단위고지혈증합병고혈압적환자112례,안조수궤분조적방법분위치료조여대조조,각56례,대조조채용상규적강압약물안록지평5mg/d진행구복치료,치료조환자재대조조치료적기출상행서서벌타정10mg/d구복.치료1개월지후비교2조환자적혈압、혈지、초민C-반응단백화불량반응발생정황. 결과 치료1개월후,량조환자적수축압화서장압균교치료전강저(대조조t=4.95、2.87,치료조t=5.03、2.94,균P＜0.01),치료조저밀도지단백담고순、삼선감유、총담고순분별위(1.75±0.68) mmol/L、(1.71±0.18) mmol/L、(3.18±0.47)mmol/L,대조조분별위(2.64±0.72) mmol/L、(1.89±0.25) mmol/L、(4.23±0.56) mmol/L),량조치료후균강저(t치분별위2.77、3.16、2.59,균P＜0.05),여대조조상비치료조적하강폭도경위명현(t치3.96、3.42,균P＜0.001)；고밀도지단백담고순(1.09±0.23) mmol/L교치료전(0.72±0.24)mmol/L증가(t=3.01,P=0.004),치료조초민C-반응단백유(4.97±0.13) mg/L하강(1.32±0.17)mg/L(t=4.40,P＜0.001).량조환자간신공능무현저적변화,미출현엄중적불량반응. 결론 서서벌타정개치료가이유효지강저혈중저밀도지단백담고순、삼선감유화초민C-반응단백,제고고밀도지단백담고순,해방안가이경유효지공제혈압.
Objective To analyze the efficacy of rosuvastatin on the patients with hyperlipidemia and hypertension.Methods From March 2011 to June 2012,112 cases with hyperlipidemia and hypertension in our hospital were enrolled in this study.Patients were randomly divided into treatment group and control group (56 patients,each).Patients in control group were treated with oral amlodipine 5 mg/d.Patients in treatment group were treated with oral rosuvastain 10 mg/d and oral amlodipine 5 mg/d.One month after the treatment,the levels of blood pressure,total cholesterol (TC),tryglyceride (TG),low density liporotein (LDL-C),high density lipoprotein cholesterol (HDL-C),high sensitivity C-reactive protein (hsCRP) were determined.The occurrence of adverse effects were observed.Results One month after treatment,systolic blood pressure and diastolic blood pressure were significantly decreased in both two groups compared with pre-treatment [Control group:(135.2±9.51)mm Hgvs.(59.2±7.3)mm Hg,(88.8±5.2)mm Hg vs.(99.5±8.3)mm Hg,t=4.95,2.87; Treatment group:(130.2±5.5)mm Hg vs.(160.3±9.3)mm Hg,(86.7± 10.2)mm Hg vs.(99.7±8.3)mm Hg,t=5.03,2.94,all P＜0.01],but more declines were found in treatment group than in control group(t=3.96,3.42,both P＜0.001).The levels of LDL-C,TG and TC were significantly decreased in both two groups compared with pre-treatment [Control group:(2.64±0.72)mmol/L vs.(3.97±0.84)mmol/L,(1.89±0.25)mmol/L vs.(2.56±0.45)mmol/L,(4.23±0.56)mmol/L vs.(7.36±0.48)mmol/L,t=2.58,3.03,2.36,P=0.013,0.004,0.022;Treatment group:(1.75 ± 0.68) mmol/L vs.(3.85 ± 0.79) mmol/L,(1.71 ± 0.18) mmol/L vs.(2.63±0.42)mmol/L,(3.18±0.47)mmol/L vs.(7.20±0.56)mmol/L,t=2.77,3.16,2.59,P=0.008,0.003,0.012,respectively],but more declines were observed in treatment group than in control group(t=6.73,4.37,10.70 respectively,all P＜0.05).The HDL-C concentrations were increased in both two groups compared with pre-treatment [Control group:(0.97±0.26)mmol/L vs.(0.75±0.31)mmol/L,t=2.89,P=0.006; Treatment group:(1.09±0.23)mmol/L vs.(0.72±0.24)mmol/L,t=3.01,P=0.004],but more increment were observed in treatment group than in control group(t=2.59,P＜0.05).The hsCRP concentration was significantly reduced in treatment group compared with pre-treatment [(1.32±0.17) mg/L vs.(4.97±0.13) mg/L,t=4.40,P＜0.001].There were no significant differences in liver and kidney function between the two groups.Serious adverse effects were not found.Conclusions Rosuvastatin combined with routine antihypertensive therapy can effectively decrease the levels of serum LDL-C,TG,hsCRP; increase serum HDL-C concentration and blood pressure can be effectively controlled.